Systemic Mastocytosis in a Child With t(8;21) Acute Myeloid Leukemia | Zendy

Mahadeo Kris M. | Zendy; Wolgast Lucia | Zendy; McMahon Christine | Zendy; Cole Peter D. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Systemic Mastocytosis in a Child With t(8;21) Acute Myeloid Leukemia

Author(s) -

Mahadeo Kris M.,

Wolgast Lucia,

McMahon Christine,

Cole Peter D.

Publication year - 2011

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.23026

Subject(s) - medicine , systemic mastocytosis , blood cancer , myeloid leukemia , asymptomatic , chemotherapy , bone marrow , myeloid , leukemia , oncology , cancer

Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c‐KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off‐treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high‐risk group despite favorable cytogenetics. Pediatr Blood Cancer 2011; 57: 684–687. © 2011 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research